All In Biotech

Investigational drug · Phase 3

New of Niraparib

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Castration-Resistant Prostatic Cancer.

Phase 3

Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

9

Any phase or sponsor naming "New of Niraparib"

First trial start

2019

Jan 25, 2019

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "New of Niraparib", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Castration-Resistant Prostatic Cancer

Approved drugs for the same conditions: Oncology · Kidney and urology

Largest trials

Live from ClinicalTrials.gov: studies naming "New of Niraparib" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 0 on PubMed

No PubMed records name it yet, which is common for early code-named drugs.

Also in development for Castration-Resistant Prostatic Cancer

  • OpevesostatMK-5684, ODM-208Phase 37 trials

    Merck & Co. · Prostate Cancer Metastatic, Malignant Neoplasm, Metastatic Castration-resistant Prostate Cancer (mCRPC)

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Johnson & Johnson (Janssen).

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.